A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

Inclusion Criteria:

• Signed informed consent.

• Diagnosis of MCC with distant metastatic disease as a component of tumor burden and no more than 3 prior systemic treatments, inclusive of systemic adjuvant therapy.

• Eastern Cooperative Oncology Group performance status of 0 to 1.

• Measurable disease according to RECIST v1.1.

• Availability of tumor tissue (fresh or archival) for central pathology review.

• Willingness to avoid pregnancy or fathering children based on protocol defined criteria.

Exclusion Criteria:**

• Prior programmed cell death protein 1 (PD-1) or programmed cell death ligand protein 1 (PD-L1)-directed therapy.
• Treatment with anticancer drugs or participation in another interventional clinical study within 21 days before the first administration of study drug.
• Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy (with the exceptions for anemia not requiring transfusion support and any grade of alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment.
• Radiation therapy administered within 2 weeks of first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment.
• Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
• History of second malignancy within 3 years (with exceptions).
• Laboratory values outside the protocol-defined range at screening.
• Clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders.
• Active bacterial, fungal, or viral infections, including hepatitis A, B, and C.
• Receipt of a live vaccine within 90 days of planned start of study therapy.
• Current use of protocol-defined prohibited medication.
• Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
• Inability or unlikely, in the opinion of the investigator, to comply with the Protocol requirements.
• Participant who is pregnant or breastfeeding.